A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme

• Sponsor: MedImmune LLC (Industry)
• Overall Status: Completed
• CT.gov ID: NCT01268566
• Collaborator: (none)
• Enrollment: 62
• Locations: 12
• Arm: 1
• Duration (Months): 22
• Patients Per Site: 5.2
• Patients Per Site Per Month: 0.2

Study Details

Study Description

Brief Summary

The primary objective of this Phase II study is to evaluate the progression-free survival at 6 months in adult subjects with a first recurrence of Glioblastoma Multiforme who are treated with MEDI-575.

Condition or Disease	Intervention/Treatment	Phase
Glioblastoma Multiforme	Drug: MEDI-575	Phase 2

Detailed Description

This is a Phase 2, multicenter, open-label, single-arm study to evaluate the antitumor activity, safety, and pharmacology of MEDI-575 in adult subjects with first recurrence of GBM.

Approximately 55 subjects will be enrolled to determine the preliminary efficacy profile of MEDI-575 in the treatment of subjects with first recurrence of GBM. Subjects will receive MEDI-575 as a 60-minute IV infusion on Day 1 every 21 days until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for subject withdrawal.

The primary assessment of antitumor activity is PFS-6; tumor response and progression will be determined using Updated Response Assessment Criteria of High Grade Gliomas- Neuro-Oncology Working Group v.1. Approximately 15 investigational sites in the United States will participate in this study. All subjects will be followed every 3 months for the duration of the trial (defined as 9 months from the date the last subject is entered into the trial or when the sponsor stops the study.

Study Design

• Study Type: Interventional
• Actual Enrollment: 62 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme
• Study Start Date: Jan 1, 2011
• Actual Primary Completion Date: Nov 1, 2012
• Actual Study Completion Date: Nov 1, 2012

Arms and Interventions

Arm	Intervention/Treatment
Experimental: MEDI-575, 25 mg/kg MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minutes on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participants withdrawal.	Drug: MEDI-575; MEDI-575 as an IV infusion.

Outcome Measures

Primary Outcome Measures

1. Progression-free Survival Rate at 6 Months [6 months]

   Progression-free survival (PFS) rate at 6 months is defined as the proportion of participants who neither progressed nor died before 6 months after the first dose. Progression was determined using Updated Response Assessment Criteria of High Grade Gliomas: Response Assessment in Neuro-Oncology Working Group (RANO criteria). Progression was defined as at least 25% increase in measurement of enhancing lesions compared with the smallest tumor measurement obtained during the study; or significant increase in T2/fluid attenuated inversion recovery (FLAIR) nonenhancing lesion compared with baseline scan or best response; or any new lesion; or clear clinical deterioration; or failure to return for evaluation as a result of death or deteriorating condition; or clear progression of nonmeasurable disease. PFS-6 was estimated using Kaplan-Meier method.

Secondary Outcome Measures

1. Percentage of Participants With Best Overall Response [Study entry through the end of the study, up to 21 months]

   Best overall response rate is calculated based upon the disease assessments recorded during the study visits using RANO criteria. Best overall response includes complete response (CR), CR with confirmation, partial response (PR), PR with confirmation, stable disease and progressive disease. Confirmed responses are those that persist on repeat imaging studies at least 4 weeks after the initial documentation of response.

2. Percentage of Participants With Objective Response [Study entry through the end of the study, up to 21 months]

   Objective response rate (ORR) is defined as the proportion of participants with confirmed CR or confirmed PR using RANO criteria. Confirmed CR and PR are those that persist on repeat imaging study for at least 4 weeks after the initial documentation of the response. CR is defined as complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks, no new lesions, stable or improved nonenhancing (T2/FLAIR) lesions, patient is off corticosteroids and stable or improved clinically. PR is defined as 50% decrease compared with baseline in the measurement of all measurable enhancing lesions sustained for at least 4 weeks, no progression of nonmeasurable disease, no new lesions, stable or improved nonenhancing (T2/FLAIR) lesions, no increase in the corticosteroid dose and stable or improved clinically.

3. Time to Response []

   Time to response (TTR) is defined as the time from the study entry to the first documentation of confirmed CR or confirmed PR. Analysis was based on responses confirmed at a repeat assessment made at least 4 weeks after the initial response, with the TTR taken as the first time the response was observed, not the confirmation assessment. TTR was estimated using Kaplan-Meier method.

4. Duration of Response []

   Duration of response is defined as the duration from the first documentation of objective disease response (ie, confirmed CR or confirmed PR) to the first documented disease progression. Duration of response was estimated using Kaplan-Meier method and evaluated only for the participants of subgroup with an objective response.

5. Time to Progression [Study entry until the first documented disease progression, up to 16 months]

   Time to progression (TTP) is defined as time from the start of treatment with MEDI-575 until the documentation of disease progression. Disease progression was defined by at least 25% increase in measurement of enhancing lesions compared with the smallest tumor measurement obtained during the study; or significant increase in T2/FLAIR nonenhancing lesion compared with baseline scan or best response; or any new lesion; or clear clinical deterioration; or failure to return for evaluation as a result of death or deteriorating condition; or clear progression of nonmeasurable disease. TTP was estimated using Kaplan-Meier method.

6. Progression-free Survival Rate at 3 Months and 9 Months [3 months and 9 months]

   PFS rate at 3 and 9 months is defined as proportion of participants who neither progressed nor died due to any cause, whichever occurred first after first dose at 3 months and 9 months, respectively. Progression was defined as at least 25% increase in measurement of enhancing lesions compared with the smallest tumor measurement obtained during the study; or significant increase in T2/FLAIR nonenhancing lesion compared with baseline scan or best response; or any new lesion; or clear clinical deterioration; or failure to return for evaluation as a result of death or deteriorating condition; or clear progression of nonmeasurable disease. Proportion of participants with PFS at 3 and 9 months were estimated using Kaplan-Meier method.

7. Progression-free Survival [9 months]

   PFS was measured from the start of treatment with MEDI-575 until the documentation of disease progression or death due to any cause, whichever occurred first. Progression was defined as at least 25% increase in measurement of enhancing lesions compared with the smallest tumor measurement obtained during the study; or significant increase in T2/FLAIR nonenhancing lesion compared with baseline scan or best response; or any new lesion; or clear clinical deterioration; or failure to return for evaluation as a result of death or deteriorating condition; or clear progression of nonmeasurable disease. PFS was censored on the date of last tumor assessment documenting absence of tumor progression for participants who have no documented progression and were still alive prior to data cutoff, dropout, or the initiation of alternate anticancer treatment. Time to PFS was estimated using Kaplan-Meier method.

8. Overall Survival [Study entry to death, up to 16 months]

   Overall survival is defined as the time from the start of treatment with MEDI-575 until death. For the participants who were alive at the end of study or lost to follow-up, Overall survival was censored on the last date when participants were known to be alive. The Overall survival was estimated using the Kaplan-Meier method.

9. Percentage of Participants With Expression of PDGFR Alpha in the Tumor Samples [Screening (Day-28 to Day -1)]

   MEDI-575 (study drug) blocks platelet-derived growth factor (PDGF) binding to PDGF receptor (PDGFR) alpha and inhibits signaling. The tissue samples which were collected prior to the study entry (archived tumor samples) were evaluated by immunohistochemistry staining for expression of PDGFR alpha signaling protein that are targets of MEDI-575. Expression of PDGFR alpha in tumor cells and tumor-associated stromal cells were evaluated for intensity and distribution of staining. The percentage of participants with positive PDGFR alpha staining in the tumor cells and tumor-associated stromal cells were reported.

10. Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events [Baseline to last record on study, up to 21 months]

    An adverse event (AE) is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. Treatment-emergent AEs (TEAEs) are AEs occurring or worsening after the administration of study drug until 90 days after the last dose of study drug or until the participant began another anticancer therapy, which ever came first. A serious AE (SAE) is any AE that results in death, is immediately life threatening, require (or prolong) inpatient hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly or birth defect, or is an important medical event that may jeopardize the participant or may require medical intervention to prevent one of the outcomes listed above. The TEAEs and SAEs were summarized using MedDRA version 15.1. Participants were counted only once for each event, regardless of number of events the participant had.

11. Number of Participants With Worst ECOG Performance Status On-study and Last Record On-study [Baseline to last record on study, up to 21 months]

    Eastern Cooperative Oncology Group (ECOG) performance status is a scale that measures how cancer affects the daily life of a participant on an ordinal scale from grade 0 (fully active ie, best) to 5 (dead ie, worst). Following are ECOG grades: 0: Fully active, perform all pre-disease activities without restriction. 1: Restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature. 2: Ambulatory, capable of selfcare, unable to carry out any work activities, up and about more than (>) 50% of waking hours. 3: Capable of limited selfcare, confined to bed or chair >50% of waking hours. 4: Completely disabled, not capable of any selfcare, totally confined to bed or chair. 5: Dead.

12. Treatment-emergent Adverse Events Related to Laboratory Parameters [Baseline to last record on study, up to 21 months]

    Laboratory evaluations of blood and urine samples were performed, including hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count with differential); serum chemistry (calcium, chloride, magnesium, potassium, sodium, aspartate transaminase, alanine transaminase, alkaline phosphatase, gamma glutamyl transferase, lactic dehydrogenase, carbon dioxide/bicarbonate, blood urea nitrogen, uric acid, creatinine, total bilirubin, glucose, albumin, total protein, triglycerides, cholesterol, phosphorous); urinalysis (pH, protein, blood, glucose, ketones, bilirubin); and coagulation parameters. Abnormal laboratory finding that required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation, was reported as an AE. Number of participants with TEAEs related to laboratory evaluations were reported.

13. Treatment-emergent Adverse Events Related to Electrocardiogram Evaluations [Baseline to last record on study, up to 21 months]

    All 12-lead electrocardiograms (ECGs) performed during the study were obtained in triplicate (ie, 3 ECGs were obtained within a 5-minute time period) and analyzed. Number of participants with TEAEs related to ECG after the start of study drug administration were reported. Participants were counted only once for each system organ class and preferred term, regardless of how many events the participants had.

14. Treatment-emergent Adverse Events Related to Vital Sign Parameters [Baseline to last record on study, up to 21 months]

    Vital sign assessments were conducted throughout the study and included body temperature, blood pressure (seated), pulse rate and respiratory rate. The TEAEs related to vital signs in participants were reported. Participants were counted only once for each system organ class and preferred term, regardless of how many events the participants had.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 95 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Written informed consent and HIPAA authorization (applies to covered entities in the USA only) obtained from the subject/legal representative prior to performing any protocol-related procedures, including screening evaluations

• Age ≥18 years old at the time of screening

• Histologically confirmed diagnosis of World Health Organization Grade IV malignant glioma (glioblastoma or gliosarcoma)

• Previous first line treatment with radiotherapy and temozolomide (treatment prior to radiation and temozolomide permitted, [ie, Gliadel])

• Documented first recurrence of GBM by diagnostic biopsy or by contrast-enhanced magnetic resonance imaging (MRI) as per Updated Response Assessment Criteria of High Grade Gliomas- Neuro-Oncology Working Group (Wen et al, 2010)

• Life expectancy ≥ 12 weeks

• Adequate hematologic and organ function

• Negative serum pregnancy test (women only)

• Two methods of birth control for female participants of child-bearing potential or male participants with their female partners of child-bearing potential

Exclusion Criteria:

• Treatment with any chemotherapy, radiotherapy, immunotherapy, biologic, hormonal therapy or investigational agent 30 days prior to study entry

• Concurrent enrollment in another clinical study involving an investigational agent

• Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals

• Previous mAb treatment specifically directed against PDGF or PDGF receptors

• Previous bevacizumab or other VEGF and anti-angiogenic treatment

• More than 1 recurrence of GBM

• Any surgery (not including minor diagnostic procedures) within 2 weeks prior to baseline disease assessments; or not fully recovered from any side effects of previous procedures

• History of serious allergy or reaction to any component of the MEDI-575 formulation

• New York Heart Association ≥ Grade 2 congestive heart failure within 6 months prior to study entry

• Uncontrolled or significant cardiovascular disease

• History of other invasive malignancy within 5 years prior to study entry except for cervical carcinoma in situ (CIS), non-melanomatous carcinoma of the skin or ductal carcinoma in situ (DCIS) of the breast that have been surgically cured

• History of active human immunodeficiency virus or active hepatitis B or C viral infection will be excluded to eliminate the risk of increased AEs due to immune compromise.

• Systemic immunosuppressive therapy.

• Subjects taking corticosteroids must be on a stable dose for 7 days prior to initiation of treatment with MEDI-575 16) Presence of extracranial metastatic or leptomeningeal disease

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Research Site	Tucson	Arizona	United States
2	Research Site	Los Angeles	California	United States
3	Research Site	Stanford	California	United States
4	Research Site	Chicago	Illinois	United States
5	Research Site	Boston	Massachusetts	United States
6	Research Site	Detroit	Michigan	United States
7	Research Site	New York	New York	United States
8	Research Site	Canton	Ohio	United States
9	Research Site	Pittsburgh	Pennsylvania	United States
10	Research Site	Nashville	Tennessee	United States
11	Research Site	San Antonio	Texas	United States
12	Research Site	Seattle	Washington	United States

Sponsors and Collaborators

• MedImmune LLC

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• CD-ON-MEDI-575-1042 Redacted CSR Synopsis

Publications

None provided.

• Responsible Party: MedImmune LLC
• ClinicalTrials.gov Identifier: NCT01268566
• Other Study ID Numbers: CD-ON-MEDI-575-1042
• First Posted: Dec 31, 2010
• Last Update Posted: Apr 6, 2017
• Last Verified: Feb 1, 2017

• Keywords provided by MedImmune LLC: Glioblastoma
• Additional relevant MeSH terms: Glioblastoma

Study Results

Participant Flow

Recruitment Details	A total of 56 subjects were enrolled and treated at 13 sites in the United States.
Pre-assignment Detail	A total of 62 participants were screened. Of which, 56 participants were enrolled into study as 5 participants failed screening and 1 participant withdrew consent.

Arm/Group Title	MEDI-575, 25 mg/kg
Arm/Group Description	MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minute on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participant withdrawal.
Period Title: Overall Study
STARTED	56
COMPLETED	13
NOT COMPLETED	43

Baseline Characteristics

Arm/Group Title	MEDI-575, 25 mg/kg
Arm/Group Description	MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minute on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participant withdrawal.
Overall Participants	56
Age (Years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [Years]	52.9 (13.5)
Sex: Female, Male (Count of Participants)
Female	19 33.9%
Male	37 66.1%

Outcome Measures

1. Primary Outcome

Title	Progression-free Survival Rate at 6 Months
Description	Progression-free survival (PFS) rate at 6 months is defined as the proportion of participants who neither progressed nor died before 6 months after the first dose. Progression was determined using Updated Response Assessment Criteria of High Grade Gliomas: Response Assessment in Neuro-Oncology Working Group (RANO criteria). Progression was defined as at least 25% increase in measurement of enhancing lesions compared with the smallest tumor measurement obtained during the study; or significant increase in T2/fluid attenuated inversion recovery (FLAIR) nonenhancing lesion compared with baseline scan or best response; or any new lesion; or clear clinical deterioration; or failure to return for evaluation as a result of death or deteriorating condition; or clear progression of nonmeasurable disease. PFS-6 was estimated using Kaplan-Meier method.
Time Frame	6 months

Outcome Measure Data

Analysis Population Description

Intent-to treat (ITT) population: All participants who entered into the study (ie, participants for whom investigator notified the interactive web response system [IWRS] that the participant met eligibility criteria and the IWRS assigned unblinded study drug to the participant).

Arm/Group Title	MEDI-575, 25 mg/kg
Arm/Group Description	MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minute on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participant withdrawal.
Measure Participants	56
Number (90% Confidence Interval) [Percentage of participants]	15.4 27.5%

2. Secondary Outcome

Title	Percentage of Participants With Best Overall Response
Description	Best overall response rate is calculated based upon the disease assessments recorded during the study visits using RANO criteria. Best overall response includes complete response (CR), CR with confirmation, partial response (PR), PR with confirmation, stable disease and progressive disease. Confirmed responses are those that persist on repeat imaging studies at least 4 weeks after the initial documentation of response.
Time Frame	Study entry through the end of the study, up to 21 months

Outcome Measure Data

Analysis Population Description

ITT population

Arm/Group Title	MEDI-575, 25 mg/kg
Arm/Group Description	MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minute on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participant withdrawal.
Measure Participants	56
Complete response with confirmation	0 0%
Complete response without confirmation	0 0%
Partial response with confirmation	0 0%
Partial response without confirmation	0 0%
Stable disease	41.1 73.4%
Progressive disease	55.4 98.9%
Unknown	3.6 6.4%

3. Secondary Outcome

Title	Percentage of Participants With Objective Response
Description	Objective response rate (ORR) is defined as the proportion of participants with confirmed CR or confirmed PR using RANO criteria. Confirmed CR and PR are those that persist on repeat imaging study for at least 4 weeks after the initial documentation of the response. CR is defined as complete disappearance of all enhancing measurable and nonmeasurable disease sustained for at least 4 weeks, no new lesions, stable or improved nonenhancing (T2/FLAIR) lesions, patient is off corticosteroids and stable or improved clinically. PR is defined as 50% decrease compared with baseline in the measurement of all measurable enhancing lesions sustained for at least 4 weeks, no progression of nonmeasurable disease, no new lesions, stable or improved nonenhancing (T2/FLAIR) lesions, no increase in the corticosteroid dose and stable or improved clinically.
Time Frame	Study entry through the end of the study, up to 21 months

Outcome Measure Data

Analysis Population Description

ITT population

Arm/Group Title	MEDI-575, 25 mg/kg
Arm/Group Description	MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minute on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participant withdrawal.
Measure Participants	56
Number (90% Confidence Interval) [Percentage of participants]	0 0%

4. Secondary Outcome

Title	Time to Response
Description	Time to response (TTR) is defined as the time from the study entry to the first documentation of confirmed CR or confirmed PR. Analysis was based on responses confirmed at a repeat assessment made at least 4 weeks after the initial response, with the TTR taken as the first time the response was observed, not the confirmation assessment. TTR was estimated using Kaplan-Meier method.

Outcome Measure Data

Analysis Population Description

ITT population with an objective response (ie, confirmed CR or PR) were assessed. TTR was not estimable as there were no participants with an objective response.

Arm/Group Title	MEDI-575, 25 mg/kg
Arm/Group Description	MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minute on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participant withdrawal.
Measure Participants	0

5. Secondary Outcome

Title	Duration of Response
Description	Duration of response is defined as the duration from the first documentation of objective disease response (ie, confirmed CR or confirmed PR) to the first documented disease progression. Duration of response was estimated using Kaplan-Meier method and evaluated only for the participants of subgroup with an objective response.

Outcome Measure Data

Analysis Population Description

ITT population with an objective response (ie, confirmed CR or PR) were assessed. Duration of response was not estimable as there were no participants with an objective response.

Arm/Group Title	MEDI-575, 25 mg/kg
Arm/Group Description	MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minute on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participant withdrawal.
Measure Participants	0

6. Secondary Outcome

Title	Time to Progression
Description	Time to progression (TTP) is defined as time from the start of treatment with MEDI-575 until the documentation of disease progression. Disease progression was defined by at least 25% increase in measurement of enhancing lesions compared with the smallest tumor measurement obtained during the study; or significant increase in T2/FLAIR nonenhancing lesion compared with baseline scan or best response; or any new lesion; or clear clinical deterioration; or failure to return for evaluation as a result of death or deteriorating condition; or clear progression of nonmeasurable disease. TTP was estimated using Kaplan-Meier method.
Time Frame	Study entry until the first documented disease progression, up to 16 months

Outcome Measure Data

Analysis Population Description

ITT population. N= number of participants analyzed for this outcome measure

Arm/Group Title	MEDI-575, 25 mg/kg
Arm/Group Description	MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minute on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participant withdrawal.
Measure Participants	48
Median (90% Confidence Interval) [Months]	1.4

7. Secondary Outcome

Title	Progression-free Survival Rate at 3 Months and 9 Months
Description	PFS rate at 3 and 9 months is defined as proportion of participants who neither progressed nor died due to any cause, whichever occurred first after first dose at 3 months and 9 months, respectively. Progression was defined as at least 25% increase in measurement of enhancing lesions compared with the smallest tumor measurement obtained during the study; or significant increase in T2/FLAIR nonenhancing lesion compared with baseline scan or best response; or any new lesion; or clear clinical deterioration; or failure to return for evaluation as a result of death or deteriorating condition; or clear progression of nonmeasurable disease. Proportion of participants with PFS at 3 and 9 months were estimated using Kaplan-Meier method.
Time Frame	3 months and 9 months

Outcome Measure Data

Analysis Population Description

ITT population

Arm/Group Title	MEDI-575, 25 mg/kg
Arm/Group Description	MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minute on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participant withdrawal.
Measure Participants	56
PFS rate at 3 months	26.5 47.3%
PFS rate at 9 months	8.8 15.7%

8. Secondary Outcome

Title	Progression-free Survival
Description	PFS was measured from the start of treatment with MEDI-575 until the documentation of disease progression or death due to any cause, whichever occurred first. Progression was defined as at least 25% increase in measurement of enhancing lesions compared with the smallest tumor measurement obtained during the study; or significant increase in T2/FLAIR nonenhancing lesion compared with baseline scan or best response; or any new lesion; or clear clinical deterioration; or failure to return for evaluation as a result of death or deteriorating condition; or clear progression of nonmeasurable disease. PFS was censored on the date of last tumor assessment documenting absence of tumor progression for participants who have no documented progression and were still alive prior to data cutoff, dropout, or the initiation of alternate anticancer treatment. Time to PFS was estimated using Kaplan-Meier method.
Time Frame	9 months

Outcome Measure Data

Analysis Population Description

ITT population. N= number of participants analyzed for this outcome measure

Arm/Group Title	MEDI-575, 25 mg/kg
Arm/Group Description	MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minute on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participant withdrawal.
Measure Participants	50
Median (90% Confidence Interval) [Months]	1.4

9. Secondary Outcome

Title	Overall Survival
Description	Overall survival is defined as the time from the start of treatment with MEDI-575 until death. For the participants who were alive at the end of study or lost to follow-up, Overall survival was censored on the last date when participants were known to be alive. The Overall survival was estimated using the Kaplan-Meier method.
Time Frame	Study entry to death, up to 16 months

Outcome Measure Data

Analysis Population Description

ITT population. N= number of participants analyzed for this outcome measure

Arm/Group Title	MEDI-575, 25 mg/kg
Arm/Group Description	MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minute on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participant withdrawal.
Measure Participants	30
Median (90% Confidence Interval) [Months]	9.7

10. Secondary Outcome

Title	Percentage of Participants With Expression of PDGFR Alpha in the Tumor Samples
Description	MEDI-575 (study drug) blocks platelet-derived growth factor (PDGF) binding to PDGF receptor (PDGFR) alpha and inhibits signaling. The tissue samples which were collected prior to the study entry (archived tumor samples) were evaluated by immunohistochemistry staining for expression of PDGFR alpha signaling protein that are targets of MEDI-575. Expression of PDGFR alpha in tumor cells and tumor-associated stromal cells were evaluated for intensity and distribution of staining. The percentage of participants with positive PDGFR alpha staining in the tumor cells and tumor-associated stromal cells were reported.
Time Frame	Screening (Day-28 to Day -1)

Outcome Measure Data

Analysis Population Description

ITT population with archived tumor samples were assessed.

Arm/Group Title	MEDI-575, 25 mg/kg
Arm/Group Description	MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minute on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participant withdrawal.
Measure Participants	39
Positive PDGFR alpha staining in tumor cells	46 82.1%
Positive staining in tumor stromal cells	26 46.4%

11. Secondary Outcome

Title	Number of Participants With Treatment-emergent Adverse Events and Serious Adverse Events
Description	An adverse event (AE) is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. Treatment-emergent AEs (TEAEs) are AEs occurring or worsening after the administration of study drug until 90 days after the last dose of study drug or until the participant began another anticancer therapy, which ever came first. A serious AE (SAE) is any AE that results in death, is immediately life threatening, require (or prolong) inpatient hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly or birth defect, or is an important medical event that may jeopardize the participant or may require medical intervention to prevent one of the outcomes listed above. The TEAEs and SAEs were summarized using MedDRA version 15.1. Participants were counted only once for each event, regardless of number of events the participant had.
Time Frame	Baseline to last record on study, up to 21 months

Outcome Measure Data

Analysis Population Description

Safety population included all participants who received at least 1 dose of MEDI-575.

Arm/Group Title	MEDI-575, 25 mg/kg
Arm/Group Description	MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minute on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participant withdrawal.
Measure Participants	56
Participants with TEAEs	50 89.3%
Participants with treatment emergent SAEs	17 30.4%

12. Secondary Outcome

Title	Number of Participants With Worst ECOG Performance Status On-study and Last Record On-study
Description	Eastern Cooperative Oncology Group (ECOG) performance status is a scale that measures how cancer affects the daily life of a participant on an ordinal scale from grade 0 (fully active ie, best) to 5 (dead ie, worst). Following are ECOG grades: 0: Fully active, perform all pre-disease activities without restriction. 1: Restricted in physically strenuous activity but ambulatory, carry out work of a light or sedentary nature. 2: Ambulatory, capable of selfcare, unable to carry out any work activities, up and about more than (>) 50% of waking hours. 3: Capable of limited selfcare, confined to bed or chair >50% of waking hours. 4: Completely disabled, not capable of any selfcare, totally confined to bed or chair. 5: Dead.
Time Frame	Baseline to last record on study, up to 21 months

Outcome Measure Data

Analysis Population Description

Safety population

Arm/Group Title	MEDI-575, 25 mg/kg
Arm/Group Description	MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minute on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participant withdrawal.
Measure Participants	56
Worst on-study: Grade 0	6 10.7%
Worst on-study: Grade 1	24 42.9%
Worst on-study: Grade 2	16 28.6%
Worst on-study: Grade 3	9 16.1%
Worst on-study: Grade 4	1 1.8%
Worst on-study: Not done	0 0%
Last record on-study: Grade 0	9 16.1%
Last record on-study: Grade 1	27 48.2%
Last record on-study: Grade 2	12 21.4%
Last record on-study: Grade 3	7 12.5%
Last record on-study: Grade 4	1 1.8%
Last record on-study: Not done	0 0%

13. Secondary Outcome

Title	Treatment-emergent Adverse Events Related to Laboratory Parameters
Description	Laboratory evaluations of blood and urine samples were performed, including hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count with differential); serum chemistry (calcium, chloride, magnesium, potassium, sodium, aspartate transaminase, alanine transaminase, alkaline phosphatase, gamma glutamyl transferase, lactic dehydrogenase, carbon dioxide/bicarbonate, blood urea nitrogen, uric acid, creatinine, total bilirubin, glucose, albumin, total protein, triglycerides, cholesterol, phosphorous); urinalysis (pH, protein, blood, glucose, ketones, bilirubin); and coagulation parameters. Abnormal laboratory finding that required an action or intervention by the investigator, or a finding judged by the investigator to represent a change beyond the range of normal physiologic fluctuation, was reported as an AE. Number of participants with TEAEs related to laboratory evaluations were reported.
Time Frame	Baseline to last record on study, up to 21 months

Outcome Measure Data

Analysis Population Description

Safety population

Arm/Group Title	MEDI-575, 25 mg/kg
Arm/Group Description	MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minute on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participant withdrawal.
Measure Participants	56
Anaemia	1 1.8%
Thrombocytopenia	2 3.6%
Activated partial thromboplastin time prolonged	1 1.8%
Lymphocyte count decreased	1 1.8%
Platelet count decreased	1 1.8%
White blood cell count increased	1 1.8%
Blood lactate dehydrogenase increased	1 1.8%
Hypokalaemia	1 1.8%
Hypomagnesaemia	1 1.8%
Hypophosphataemia	1 1.8%
Haematuria	2 3.6%
Urinary tract infection	4 7.1%

14. Secondary Outcome

Title	Treatment-emergent Adverse Events Related to Electrocardiogram Evaluations
Description	All 12-lead electrocardiograms (ECGs) performed during the study were obtained in triplicate (ie, 3 ECGs were obtained within a 5-minute time period) and analyzed. Number of participants with TEAEs related to ECG after the start of study drug administration were reported. Participants were counted only once for each system organ class and preferred term, regardless of how many events the participants had.
Time Frame	Baseline to last record on study, up to 21 months

Outcome Measure Data

Analysis Population Description

Safety population

Arm/Group Title	MEDI-575, 25 mg/kg
Arm/Group Description	MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minute on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participant withdrawal.
Measure Participants	56
Abnormal ECG T wave	1 1.8%
Bradycardia	1 1.8%
Sinus bradycardia	1 1.8%

15. Secondary Outcome

Title	Treatment-emergent Adverse Events Related to Vital Sign Parameters
Description	Vital sign assessments were conducted throughout the study and included body temperature, blood pressure (seated), pulse rate and respiratory rate. The TEAEs related to vital signs in participants were reported. Participants were counted only once for each system organ class and preferred term, regardless of how many events the participants had.
Time Frame	Baseline to last record on study, up to 21 months

Outcome Measure Data

Analysis Population Description

Safety population

Arm/Group Title	MEDI-575, 25 mg/kg
Arm/Group Description	MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minute on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participant withdrawal.
Measure Participants	56
Hypertension	2 3.6%
Hypotension	2 3.6%
Heart rate increased	1 1.8%
Pyrexia	1 1.8%

Adverse Events

Time Frame	Baseline to last record on study, up to 21 months
Arm/Group Title	MEDI-575, 25 mg/kg
Arm/Group Description	MEDI-575 administered as an intravenous infusion at 25 mg/kg over a period of 60-minute on Day 1 of each 21-day cycle until disease progression, initiation of alternative anticancer therapy, unacceptable toxicity, or other reasons for participant withdrawal.
All Cause Mortality
	MEDI-575, 25 mg/kg
	Affected / at Risk (%)	# Events
Total	/ (NaN)
Serious Adverse Events
	MEDI-575, 25 mg/kg
	Affected / at Risk (%)	# Events
Total	17/56 (30.4%)
Cardiac disorders
Cardiac failure	1/56 (1.8%)	2
Gastrointestinal disorders
Anal fissure	1/56 (1.8%)	1
Diverticular perforation	1/56 (1.8%)	1
Dysphagia	1/56 (1.8%)	1
Infections and infestations
Cellulitis	1/56 (1.8%)	1
Pneumonia	2/56 (3.6%)	2
Sepsis	1/56 (1.8%)	1
Injury, poisoning and procedural complications
Fall	2/56 (3.6%)	2
Rib fracture	1/56 (1.8%)	1
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Glioblastoma multiforme	1/56 (1.8%)	1
Nervous system disorders
Brain oedema	1/56 (1.8%)	1
Cerebral cyst	1/56 (1.8%)	1
Convulsion	5/56 (8.9%)	5
Headache	1/56 (1.8%)	1
Hydrocephalus	3/56 (5.4%)	4
Ischaemic stroke	1/56 (1.8%)	1
Somnolence	1/56 (1.8%)	1
Subarachnoid haemorrhage	1/56 (1.8%)	1
Psychiatric disorders
Confusional state	1/56 (1.8%)	1
Mental status changes	1/56 (1.8%)	1
Renal and urinary disorders
Nephrolithiasis	1/56 (1.8%)	1
Respiratory, thoracic and mediastinal disorders
Respiratory failure	1/56 (1.8%)	1
Other (Not Including Serious) Adverse Events
	MEDI-575, 25 mg/kg
	Affected / at Risk (%)	# Events
Total	43/56 (76.8%)
Gastrointestinal disorders
Constipation	4/56 (7.1%)	5
Diarrhoea	13/56 (23.2%)	18
Nausea	13/56 (23.2%)	16
Vomiting	4/56 (7.1%)	4
General disorders
Fatigue	16/56 (28.6%)	19
Gait disturbance	6/56 (10.7%)	6
Oedema peripheral	5/56 (8.9%)	5
Infections and infestations
Sinusitis	3/56 (5.4%)	3
Upper respiratory tract infection	4/56 (7.1%)	4
Urinary tract infection	4/56 (7.1%)	4
Metabolism and nutrition disorders
Decreased appetite	4/56 (7.1%)	4
Musculoskeletal and connective tissue disorders
Muscle spasms	4/56 (7.1%)	6
Nervous system disorders
Aphasia	7/56 (12.5%)	9
Cognitive disorder	3/56 (5.4%)	3
Convulsion	3/56 (5.4%)	3
Dizziness	7/56 (12.5%)	8
Headache	9/56 (16.1%)	11
Hemiparesis	4/56 (7.1%)	4
Memory impairment	6/56 (10.7%)	6
Psychiatric disorders
Confusional state	3/56 (5.4%)	3
Insomnia	6/56 (10.7%)	6
Respiratory, thoracic and mediastinal disorders
Cough	4/56 (7.1%)	4
Oropharyngeal pain	3/56 (5.4%)	3

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.